{
    "clinical_study": {
        "@rank": "23640", 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effectiveness and safety of atomoxetine in the\n      treatment of adolescents with coexisting alcohol or substance use disorders and Attention\n      Deficit Hyperactivity Disorder (ADHD)."
        }, 
        "brief_title": "Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD", 
        "completion_date": {
            "#text": "July 2007", 
            "@type": "Actual"
        }, 
        "condition": [
            "Substance Use Disorders", 
            "Attention Deficit Hyperactivity Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Substance-Related Disorders", 
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adolescents, ages 13-18\n\n          -  Meets criteria for alcohol and/or substance use disorder and attention deficit\n             hyperactivity disorder.\n\n        Exclusion Criteria:\n\n          -  Adolescents who are pregnant.\n\n          -  Have a history of seizure disorder, other neurological or medical disorder for which\n             medication treatment may present a considerable risk.\n\n          -  History of pervasive development disorder, schizophrenia or other psychotic\n             disorders, organic mental disorders or eating disorders.\n\n          -  Currently on other psychotropic medications from which discontinuation would present\n             a significant risk.\n\n          -  A current episode of major depressive disorder or a diagnosis of bipolar disorder.\n\n          -  Diagnosis of dependence for any substance other than marijuana.\n\n          -  Adolescents with a full-scale IQ below 80."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00029614", 
            "org_study_id": "NIAAABUK00301", 
            "secondary_id": [
                "K24AA000301", 
                "NIH Grant 5K24AA000301-05"
            ]
        }, 
        "intervention": {
            "intervention_name": "Atomoxetine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Atomoxetine"
        }, 
        "keyword": [
            "ADHD", 
            "Substance Use"
        ], 
        "lastchanged_date": "April 27, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15213"
                }, 
                "name": "Western Psychiatric Institute and Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Psychopharmacology of Adolescents With AUD and ADHD", 
        "overall_official": {
            "affiliation": "Western Psychiatric Institute and Clinic", 
            "last_name": "Oscar G. Bukstein, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": [
            {
                "measure": "decrease in ADHD symptoms"
            }, 
            {
                "measure": "decrease in the quantity and frequency of alcohol and other substance use"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00029614"
        }, 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2006", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2010"
    }, 
    "geocoordinates": {
        "Western Psychiatric Institute and Clinic": "40.441 -79.996"
    }
}